Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

Researchers from the University of Virginia in Charlottesville have discovered a type of gut bacteria that could prove effective where other types of helpful bacteria have failed in the fight against ...

The U.S. Food and Drug Administration issued a warning after a patient died following a fecal transplant procedure to treat C. difficile. Clostridium difficile is an infection of the intestines that ...

Fecal microbiota transplantation (FMT), shown to be effective in the treatment of recurrent Clostridioides difficile infection (CDI), also shows significant benefit in the treatment of primary CDI, ...

Fidaxomicin should be the antibiotic of choice when treating adults with Clostridioides difficile infection, according to new guidance from the Infectious Diseases Society of America and the Society ...

Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C difficile Education & Advocacy, explained how FDA-approved microbiome-based therapeutics help to treat and ...

The Food and Drug Administration has approved a fecal microbiota pill to treat recurrent infections caused by Clostridium difficile (C. diff), an antibiotic-resistant bacterium deemed an urgent threat ...

Current guidelines recommend using either metronidazole or vancomycin to treat C. diff infections. “For many years the two antibiotics were considered to be equivalent in their ability to cure C. diff ...

A recent Centers for Disease Control and Prevention report found 75 percent of patients in a group of 10,342 cases were already colonized with C. difficile at the time of hospital admission, according ...

Paul Feuerstadt, MD, and Louis Korman, MD, spoke with Becker’s about how a study published in The New England Journal of Medicine could change how the gastroenterology industry treats Clostridioides ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

In vitro, treatment with UDCA significantly decreased C. diff spore germination, growth and toxin activity. In the mouse model, pre-treatment with UDCA had some effect on bacterial growth, but the ...